2016 US Venture Capital Investment into Life Sciences Companies: An Analysis by Evolution Bioscience

In order to elucidate the focus of Venture Capital funding in the Biotechnology sector this year, Evolution Analysts have assessed the deals carried out by the Top 25 US Venture

Will Mesoblast recover from Teva & Celgene setbacks?

Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, with their key US

Texcell acquisition of Vivo Science underscores the shifting Biopharma Contract Services landscape

Texcell, a French provider of biosafety contract services, recently acquired German company Vivo Science GmbH, a GLP/GMP compliant contract research test facility specialising in toxicology, immunology & virology in vivo

Evolution Infographic: The Rise & Diversification of Biologics

For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and

Evolution Analysis – Google, Sanofi, Novartis and the Race to Improve Diabetes Health Outcomes

On August 31, 2015 Google Life Sciences and French pharma giant Sanofi announced that the two companies will work together on new digital technology and tools for the treatment of

Record-setting IPO for cancer immunotherapy company NantKwest

NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer,

Charles River Labs to Acquire Rapid Bacterial Detection System Provider Celsis International

Preclinical CRO Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject

Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies

Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic